Mohamad Mohty

Active 2000–2025

482
Papers
48,765
Citations
126
h-index
450
i10-index

Citations

Citations per year for Mohamad Mohty1988: 1 citations1997: 1 citations1999: 1 citations2001: 2 citations2002: 2 citations2003: 23 citations2004: 15 citations2005: 23 citations2006: 13 citations2007: 34 citations2008: 27 citations2009: 52 citations2010: 86 citations2011: 102 citations2012: 106 citations2013: 142 citations2014: 179 citations2015: 189 citations2016: 197 citations2017: 225 citations2018: 207 citations2019: 1,265 citations2020: 1,872 citations2021: 1,974 citations2022: 1,733 citations2023: 1,381 citations2024: 2,807 citations2025: 1,190 citations2026: 19 citations1989–1996: no citations, so these years are not shown1998: no citations, so this year is not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,773 citing papers, 20.5% of this breakdownGermany: 1,403 citing papers, 7.6% of this breakdownFrance: 1,276 citing papers, 7% of this breakdownItaly: 1,265 citing papers, 6.9% of this breakdownChina: 1,160 citing papers, 6.3% of this breakdownUnited Kingdom: 1,090 citing papers, 5.9% of this breakdownSpain: 891 citing papers, 4.9% of this breakdownNetherlands: 667 citing papers, 3.6% of this breakdownCanada: 558 citing papers, 3% of this breakdownSwitzerland: 447 citing papers, 2.4% of this breakdownJapan: 443 citing papers, 2.4% of this breakdownAustralia: 426 citing papers, 2.3% of this breakdown
0%20.5%Other 27.2%

Fields

  • Medicine82.7%
  • Biochemistry, Genetics and Molecular Biology7.9%
  • Immunology and Microbiology6.8%
  • Computer Science0.7%
  • Engineering0.2%
  • Health Professions0.2%
  • Other1.5%

Topics

  • Hematopoietic Stem Cell Transplantation9.6%
  • CAR-T cell therapy research6.8%
  • Acute Myeloid Leukemia Research6.3%
  • Multiple Myeloma Research and Treatments5.9%
  • Acute Lymphoblastic Leukemia research3.9%
  • Immune Cell Function and Interaction3.2%
  • Other64.3%

Coauthors

All papers

Open in search
  1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 cited by 564

  2. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roch Houot, Franck Morschhauser - Nature Medicine 2022 cited by 383

  3. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 865

  4. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , D. Chen, Radovan Vrḫovac, John G. Gribben, Nicolaus Kröger, Hermann Einsele, Ibrahim Yakoub‐Agha - Annals of Oncology 2021 cited by 422

  5. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charlotte Graham, Deborah Yallop, Agnieszka Jóźwik, Antonio Pagliuca, Ghulam Mufti, Piers Patten, Shireen Kassam, Stephen Devereux, Majid Kazmi, Kirsty Cuthill, Victoria Potter, Andrea Kühnl, Victoria Metaxa, Laarni Bonganay, Orla Stewart, Rose Ellard, Lorraine Catt, Jen Lewis, Farzin Farzaneh, Jackie Chappell, Alice Mason, Vicky Chu, Alan Dunlop, Adeel Saleem, Gary Cheung, Helena Munro, Elka Giemza, Waseem Qasim, Paul Veys, Oana Ciocârlie, Giovanna Lucchini, Danielle Pinner, Jan Chu, Persis Amrolia, Kanchan Rao, Robert Chiesa, Juliana Silva, Annette Hill, Maria Finch, Lindsey Young, Harvinder Hara, Sujith Samarasinghe, Anupama Rao, Ajay Vora, Anupama Rao, Christine Rivat, Clare Murphy, Gulrukh Ahsan, Rasha Said Shamsah, Jesmina James, Sarah Inglott, Gary Wright, Stuart Adams, Natalia Izotova, Nitin Jain, Marina Konopleva, William G. Wierda, Elias Jabbour, Hagop M. Kantarjian, Partow Kebrieai, Emily Jones, Kara McGee, Marcela V. Maus, Matthew J. Frigault, Jami Brown, Vesselina Toncheva, Keagan S. Casey, Hanno Hock, Meaghan A McKeown, Richard Mathews and 40 more - The Lancet 2020 cited by 360

  6. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 cited by 240

  7. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 cited by 380

  8. Acute lymphoblastic leukaemia

    Authors: , - The Lancet 2020 cited by 735

  9. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raymond L. Comenzo, Monika Engelhardt, Thomas Illmer, Philip Vlummens, Chantal Doyen, Thierry Façon, Lionel Karlin, Aurore Perrot, Klaus Podar, Michael Kauffman, Sharon Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, Jean‐Richard Saint‐Martin, Marsha Crochiere, Hua Chang, Samir Parekh, Yosef Landesman, Jatin J. Shah, Paul G. Richardson, Sundar Jagannath - New England Journal of Medicine 2019 cited by 673

  10. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2020 cited by 538

  11. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

    Authors: , , , , , , , , , , , , , , , , , , , - Bone Marrow Transplantation 2022 cited by 368

  12. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vicky Chu, Kirsty Cuthill, Steven Devereux, Alan Dunlop, Rose Ellard, Farzin Farzeneh, Najeem Folarin, Elka Giemza, Shireen Kassam, Majid Kazmi, Andrea Kühnl, Jen Lewis, M.Yu. Liskova, Alice Mason, Victoria Metaxa, Ghulam Mufti, Helena Munro, Antonio Pagliuca, Piers Patten, Victoria Potter, Carmel Rice, Adeel Saleem, Robin Sanderson, Orla Stewart, Elias Jabbour, Nitin Jain, Emily Jones, Hagop M. Kantarjian, Partow Kebriaei, Marina Konopleva, Kara McGee, William G. Wierda, Jami Brown, Keagan S. Casey, Matthew J. Frigault, Hanno Hock, Richard Mathews, Marcela V. Maus, Meaghan A McKeown, Thomas R. Spitzer, Vesselina Toncheva, Élie Azoulay, Nicolas Boissel, Sophie Caillat‐Zucman, Karine Celli‐Lebras, Emmanuelle Clappier, Raphaël Itzykson, Jérôme Larghero, Étienne Lengliné, Isabelle Madelaine, Martine Meunier, Florence Rabian, Emmanuel Raffoux, Marie-Thérèse Tremorin, Agnès Bonnin, Éolia Brissot, Anne Daguenel-Nguyen, Rémy Duléry, Tounes Ledraa, Florent Malard, Clémence Mediavilla, Mohamad Mohty, Anne Vekhoff, Takanori Teshima, Koji Kato - The Lancet Haematology 2022 cited by 136

  13. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2019 cited by 357

  14. Acute graft-versus-host disease

    Authors: , , , , - Nature Reviews Disease Primers 2023 cited by 243

  15. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

    Authors: , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 138

  16. Introduction to host microbiome symbiosis in health and disease

    Authors: , , , - Mucosal Immunology 2020 cited by 207

  17. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tom Willis, Malek Faham, Kenneth C. Anderson, Jean‐Luc Harousseau, Xavier Leleu, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Nikhil C. Munshi - Blood 2018 cited by 420

  18. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

    Authors: , , , , , , , , , , , , , , , , - Bone Marrow Transplantation 2021 cited by 428

  19. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 148

  20. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 243

  21. Multiple myeloma

    Authors: , , , , , , , - Nature Reviews Disease Primers 2024 cited by 257

  22. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Bone Marrow Transplantation 2019 cited by 351

  23. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2024 cited by 222

  24. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2023 cited by 77